Parexel is expanding its efforts in so-called model-based drug development, using data analytics to flesh out a drug's potential safety, efficacy and interactions before beginning a clinical trial.
Preclinical CRO Charles River Laboratories is paying $212 million in cash to buy a company focused on quality-control testing, expanding its presence in the market for bacterial detection services.
CRO BioClinica inked a deal to acquire MediciGroup, a patient recruitment and retention outfit that uses technology to keep subjects engaged in trials and minimize dropouts.
Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.
GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.
French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost.
PRA Health Sciences, a year removed from its $300 million IPO, unveiled an end-to-end technology platform that pools trial design, planning and monitoring in one place, touting its new offering as a major step forward for the CRO.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.
Huntingdon Life Sciences, a year removed from acquiring Harlan Laboratories, is changing the combined company's name to Envigo as it works to expand its presence on the CRO market.
CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.
Massachusetts CRO Veristat has cut the ribbon on its new West Coast base, opening a Bay Area operation in an effort to maintain its recent growth.
Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.
AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.
Swedish drug developer Recipharm bought a local CRO for 15.1 million kronor ($6.2 million), fleshing out its chemistry services as it works to expand its share of the European market.
India's GVK BioSciences, marred by a data scandal, has signed an exclusive deal with Swedish drug developer Medivir, agreeing to handle the bulk of the biotech's chemistry work.
As regulators and payers place increasing importance on real-world data, CRO PPD is working to expand its reach in the field, joining forces with a division of insurance giant Anthem.
Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise.